E-DRUG: Blacklists and the AFDRAN network

------------------------------------------------------

I would like to know more about the AFDRAN network (ie, where
located, etc). Recently when visiting East Africa, it was interesting
to note how common to all three main East African countries this
problems was.

I would suggest that there it is pointless to keep a list of
'problem manufacturers, unless there is something to be done about
those on the list. Also consider legal implications, which might
apply in the case that one is keeping this sort of data, with all
that it would imply. All inspection procedures (whether done by
country regulatory authorities, or by independent, but widely
recognised bodies) ) are meant to identify such manufacturers.
Regulatory authorities ought to follow such reports and ensure
that such manufcaturers improve (as directed) or failure to that,
steps taken to stop manufacturing. That these companies contiune
to exist indicates difficulties with implementation of regulatory
directives, besides other issues.

What would be the benefit in keeping a list of poor performers, when
that would not in itself prevent them from trading with those who do
not know about all these debates around quality and safety of
medicinal products? One would suggest that the simplest thing (which
would protect the patient) would be to redefine regulatory terms of
reference, with a view to stop those bad companies from operating. I
guess the question is who has the power in thiswhole affair? Is it
the rogue manufacturers, or the regulatory authorities and those
whom they represent (end- users)? If the latter is true, then serious
measures can be taken.

Sincerely,

Bonnie Fundafunda
Marketing Manager
ECHO International Health Services Limited
Ullswater Crescent, Coulsdon, Surrey CR5 2HR, UK
Tel: +44 (0)181 660 2220
Fax: +44 (0)181 668 0751
email: bfunda@echohealth.org.uk

--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.